FDA opinion received, indicating high probability of “De Novo” classification.
Topics
FDA opinion received, indicating high probability of “De Novo” classification
2024.02.19
Recent Posts
- FDA opinion received, indicating high probability of “De Novo” classification
- Conclusion of a Collaboration Agreement with Solasia Pharma Co., Ltd. to Jointly Commercialize a Pharmaceutical Business.
- New references were added for ProteoGREEN-gGlu, FeRhoNox-1, CopperGREEN, FerroFarRed, CaTM-3 AM, SaraFluor 700-COOH, DAF-FM DA, DAR-4M AM
- Changes of Board members
- Goryo Products are now available world wide through Merck KGaA, Darmstadt, Germany and MilliporeSigma in North America.
Categories
Contact Us
